文章预览
A phase II safety and efficacy study of PM8002/BNT327 in combination with chemotherapy in patients with EGFR-mutated non-small cell lung cancer (NSCLC) Background PM8002/BNT327 is a bispecific antibody targeting PD-L1 and VEGF-A. Here we present data from an ongoing single-arm Phase II study of PM8002/BNT327 combined with chemotherapy for patients with EGFR-mutated NSCLC who progressed after EGFR-TKI treatment. The correlation between tumor PD-L1 expression and clinical response was investigated. Methods Patients received PM8002/BNT327 plus carboplatin and pemetrexed Q3W for 4 cycles, followed by maintenance with PM8002/BNT327 and pemetrexed. The primary endpoint is ORR (RECIST v1.1). Analysis by PD-L1 expression was determined by immunohistochemistry (IHC with E1L3N clone; using tumor proportion score (TPS)) in biopsy taken after progression on EGFR-TKI therapy and classified based on TPS as negative (＜1%), low expression (1 to 49%), or high expression (≥50%). Results As of Ap
………………………………
